Page last updated: 2024-12-09

5-chloro-1h-benzimidazole-2-thiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-chloro-1H-benzimidazole-2-thiol: trypanocidal [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2056429
CHEMBL ID69086
SCHEMBL ID482225
SCHEMBL ID16198099
MeSH IDM000606861

Synonyms (59)

Synonym
HMS1680N20
EN300-17325
BB 0240723
6-chloro-1h-benzoimidazole-2-thiol
nsc-45283
nsc45283
2-benzimidazolinethione, 5-chloro-
5-chloro-2-benzimidazolethiol
5-chloro-2-mercaptobenzimidazole
2-benzimidazolethiol, 5-chloro-
nsc-35063
nsc35063
25369-78-2
EU-0083057
5-chloro-1,3-dihydro-2h-benzimidazole-2-thione
smr000020099
MLS000085362 ,
5-chloro-2(3)-benzimidazolethione
einecs 246-903-5
nsc 35063
5-chloro-1h-benzimidazole-2-thiol
STK392295
C1590
AKOS000283128
AKOS000265422
AKOS000268239
CHEMBL69086 ,
5-chloro-1,3-dihydrobenzimidazole-2-thione
BBL003399
6-chloro-1h-1,3-benzodiazole-2-thiol
5-chlorobenzimidazole-2-thiol
HMS2169L05
6-chloro-1h-benzimidazole-2-thiol
FT-0638511
6-chloro-1h-benzo[d]imidazole-2-thiol
HMS3308N15
SCHEMBL482225
5-chloranyl-1,3-dihydrobenzimidazole-2-thione
bdbm42928
cid_2056429
2-mercapto-5-chlorobenzimidazole
5-chloro-2-mercapto-1h-benzimidazole
6-chloro-2-mercaptobenzimidazole
ZZIHEYOZBRPWMB-UHFFFAOYSA-N
5-chloro-1h-benzo[d]imidazole-2(3h)-thione
5-chloro-1h-benzoimidazole-2-thiol
5-chloro-benzimidazole-2-thiol
W-202069
CS-10353
SCHEMBL16198099
mfcd01658762
DTXSID80180011
5-chloro-1h benzimidazole-2-thiol
5-chloro-1h-benzo[d]imidazole-2-thiol
6-chloro-2-mercapto-1h-benzimidazole
5-chloro-1,3-dihydro-2h-benzo[d]imidazole-2-thione
CS-0094540
W11166
bdbm50570907
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency3.16230.025120.237639.8107AID886
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
15-lipoxygenase, partialHomo sapiens (human)Potency15.84890.012610.691788.5700AID887
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency8.91250.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
hypothetical protein, conservedTrypanosoma bruceiPotency44.66840.223911.245135.4813AID624173
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency10.00000.28189.721235.4813AID2326
67.9K proteinVaccinia virusPotency12.58930.00018.4406100.0000AID720580
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.58490.035520.977089.1251AID504332
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency10.00000.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency28.18380.006026.168889.1251AID540317
DNA polymerase betaHomo sapiens (human)Potency3.98110.022421.010289.1251AID485314
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency10.62130.168316.404067.0158AID720504
Guanine nucleotide-binding protein GHomo sapiens (human)Potency3.98111.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)IC50 (µMol)5.27000.270026.3638100.0000AID504719
DNA dC->dU-editing enzyme APOBEC-3A isoform aHomo sapiens (human)IC50 (µMol)100.00001.480014.526761.2000AID504722
Proteasome subunit beta type-8Homo sapiens (human)IC50 (µMol)62.00000.00130.36985.0000AID1763210
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
antigen processing and presentationProteasome subunit beta type-8Homo sapiens (human)
fat cell differentiationProteasome subunit beta type-8Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-8Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
adaptive immune responseHepatitis A virus cellular receptor 2Homo sapiens (human)
macrophage activation involved in immune responseHepatitis A virus cellular receptor 2Homo sapiens (human)
natural killer cell tolerance inductionHepatitis A virus cellular receptor 2Homo sapiens (human)
regulation of tolerance induction dependent upon immune responseHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of T-helper 1 type immune responseHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell targetHepatitis A virus cellular receptor 2Homo sapiens (human)
inflammatory responseHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of gene expressionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of myeloid dendritic cell activationHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of interferon-alpha productionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of type II interferon productionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of interleukin-2 productionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of interleukin-3 productionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of interleukin-6 productionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of tumor necrosis factor productionHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of chemokine productionHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of type II interferon productionHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of interleukin-1 productionHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of interleukin-4 productionHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of natural killer cell activationHepatitis A virus cellular receptor 2Homo sapiens (human)
toll-like receptor 3 signaling pathwayHepatitis A virus cellular receptor 2Homo sapiens (human)
toll-like receptor 7 signaling pathwayHepatitis A virus cellular receptor 2Homo sapiens (human)
toll-like receptor 9 signaling pathwayHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of T cell proliferationHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of T cell proliferationHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of macrophage activationHepatitis A virus cellular receptor 2Homo sapiens (human)
innate immune responseHepatitis A virus cellular receptor 2Homo sapiens (human)
defense response to Gram-positive bacteriumHepatitis A virus cellular receptor 2Homo sapiens (human)
maternal process involved in female pregnancyHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeHepatitis A virus cellular receptor 2Homo sapiens (human)
cellular response to lipopolysaccharideHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of granulocyte colony-stimulating factor productionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of defense response to bacteriumHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of defense response to bacteriumHepatitis A virus cellular receptor 2Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of immunological synapse formationHepatitis A virus cellular receptor 2Homo sapiens (human)
negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cellHepatitis A virus cellular receptor 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIHepatitis A virus cellular receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
threonine-type endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
protein bindingProteasome subunit beta type-8Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
protein bindingHepatitis A virus cellular receptor 2Homo sapiens (human)
metal ion bindingHepatitis A virus cellular receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
nucleoplasmProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-8Homo sapiens (human)
proteasome complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-8Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-8Homo sapiens (human)
nucleusProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
immunological synapseHepatitis A virus cellular receptor 2Homo sapiens (human)
early endosomeHepatitis A virus cellular receptor 2Homo sapiens (human)
cell surfaceHepatitis A virus cellular receptor 2Homo sapiens (human)
anchoring junctionHepatitis A virus cellular receptor 2Homo sapiens (human)
mediator complexHepatitis A virus cellular receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1763217Glutathione reactivity of compound at pH 9 measured by HPLC-MS assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID67529The compound was tested in vitro against the protozoa Entamoeba histolytica, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID75268The compound was tested in vitro against the protozoa Giardia lamblia, for the inhibition of tubulin polymerization in rat brain2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID1785232Binding affinity to human TIM-3 IgV domain (residues 22 to 130) expressed in Escherichia coli BL21 (DE3) by 1H-15N SOFAST-HMQC spectroscopic analysis2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3).
AID1763214Glutathione reactivity of compound at pH 7.5 measured by HPLC-MS assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID1763210Inhibition of human chymotrypsin-like beta 5i subunit of iCP using suc-LLVY-AMC as flurogenic substrate for 90 mins by fluorescence-based assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID1763216Glutathione reactivity of compound at pH 8.5 measured by HPLC-MS assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID1763224Thiol reactivity of the compound assessed as TNB2-depletion at 200 uM measured upto 24 hrs by TNB2-depletion assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID210973Percentage viability reduction of Trichinella spiralis muscle larvae after 3 days of incubation2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and antiparasitic activity of 1H-benzimidazole derivatives.
AID1763213Glutathione reactivity of compound measured after 24 hrs by NMR based assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID284279Antiamnesic activity against Entamoeba histolytica2007Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2
Molecular modeling of some 1H-benzimidazole derivatives with biological activity against Entamoeba histolytica: a comparative molecular field analysis study.
AID1763215Glutathione reactivity of compound at pH 8 measured by HPLC-MS assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID1763219Inhibition of beta 5 chymotrypsin-like activity (unknown origin) at 100 uM using Suc-LLVY-AMC as substrate for 90 mins by fluorescence based assay2021European journal of medicinal chemistry, Jul-05, Volume: 219Discovery of selective fragment-sized immunoproteasome inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's6 (50.00)24.3611
2020's3 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]